Adaptive Biotechnologies utilizes the adaptive immune system to develop diagnostics and therapeutics, focusing on immune medicine and clinical diagnostics.

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

COM:ADAPTIVEBIOTECH

Adaptive Biotechnologies

Last Close

4.37

22/11 16:51

Market Cap

660.42M

Beta: -

Volume Today

540.43K

Avg: -

locale

market

industry

website

ipo date

peer of

Metrics